Completed Clinical Trials

Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 30

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment

Study ID Numbers: VS-6063-203

Study First Received: December 2, 2013

Last Updated: February 1, 2017

Estimated Primary Completion Date: January 2017


Primary Outcome Measures:

Assess biomarker responses to VS-6063 in tumor tissue|Evaluate the safety of VS-6063 (defactinib)|Evaluate the pharmacokinetics of VS-6063 (defactinib)|To evaluate the tumor response to VS-6063 (defactinib)

Sponsors and Collaborators:

Verastem, Inc.

Website Link:

Leave a Reply

Call Now